HIMS News and Press, Hims & Hers Health Inc. Class A From 05/08/24

2024-05-08 10:44:13 ET Summary Hims & Hers is showing strong operating leverage and maintaining high growth, which should continue in future quarters. The CEO's recent tweets on the Israel/Gaza situation are unfortunate from an investor perspective, but the business impact is ...

2024-05-08 08:30:00 ET Growth stocks have resoundingly outperformed value and dividend stocks since the 2008 financial crisis. While this trend is a reversal relative to historical norms, growth stocks are likely to continue to deliver outstanding returns over the long term due to the emerg...

2024-05-08 03:31:58 ET Summary Hims & Hers reported strong Q1 FY24 earnings, with revenue and earnings growing 46% and 434% YoY respectively, as the number of subscribers opting for a personalized product grew 176%. The company is focused on growing its personalized solutions ...

2024-05-07 18:00:04 ET Glen Santangelo from Jefferies issued a price target of $14.00 for HIMS on 2024-05-07 16:03:00. The adjusted price target was set to $14.00. At the time of the announcement, HIMS was trading at $12.35. The overall price target consensus is at $12.8...

2024-05-07 15:35:00 ET Shares of growth stock Hims & Hers Health (NYSE: HIMS) jumped as much as 17.1% in trading on Tuesday after the company reported first-quarter 2024 financial results. As of 3 p.m. ET, shares were holding about an 8.4% gain for the day. Hims & He...

2024-05-07 13:59:04 ET Summary Hims & Hers Health, Inc. is leading in personalized health and building a strong health and wellness platform, leading to strong subscription growth. The company reported profitable growth in Q1 '24, with positive cash flows from adjusted profits...

2024-05-07 11:56:30 ET DENVER, Colo., May 07, 2024 ( 247marketnews.com )- Kraig Biocraft Laboratories (OTCQB: KBLB ), Hims & Hers Health, Inc. (NYSE: HIMS ), Nuwellis (Nasdaq: NUWE ), Clearmind Medicine Inc. (Nasdaq: CMND ), and reAlpha Tech (Na...

2024-05-07 11:15:03 ET Seaport Global analyst issues BUY recommendation for HIMS on May 7, 2024 09:28AM ET. The previous analyst recommendation was Buy. HIMS was trading at $12.5514 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...

2024-05-06 20:11:09 ET Hims & Hers Health, Inc. (HIMS) Q1 2024 Earnings Conference Call May 06, 2024, 05:00 PM ET Company Participants Bill Newby - Head, IR Andrew Dudum - Co-Founder and CEO Yemi Okupe - CFO Conference Call Participants Allen Lutz...

2024-05-06 16:54:48 ET More on Hims & Hers Health Hims & Hers Health: An Unforced Error Hims & Hers Health: Becoming A Market Leader Within The Growing Digital Health Industry Hims & Hers Health: Strong Prospects But Weak Business Model Consolidation ...